Catalyst’s FIX Gene Therapy More Effective Than Padua in Early Study

Catalyst’s FIX Gene Therapy More Effective Than Padua in Early Study

292692

Catalyst’s FIX Gene Therapy More Effective Than Padua in Early Study

An investigational gene therapy for hemophilia B, called CB 2679d-GT, increased factor IX (FIX) levels and significantly reduced bleeding in a mouse model of the disease, a preclinical study demonstrated. The clotting activity of this potential therapy, being developed by Catalyst Biosciences, also “significantly outperformed the R338L-Padua variant,” its researchers reported. The study, “Gene Therapy For Hemophilia B Using CB 2679d-GT: A Novel Factor IX Variant With Higher Potency Than Factor IX Padua,” was published in…

You must be logged in to read/download the full post.